VitaWild was different
doi:10.1038/srep09397 Onggo JR, Onggo JD, de Steiger R, Hau R
Medications known as GLP-1 receptor agonists, widely used to manage Type 2 diabetes and support weight loss, are now being linked to a modest increase in the risk of erectile dysfunction (ED), according to a recent 2026 study using a target trial emulation design published in the Journal eClinicalMedicine
Storage Instructions: Refrigeration is required for storage, but is not required during shipping
Health history, goals, lifestyle, and response to treatment are all considered when building a plan
Current trial status and protocol details can be verified via ClinicalTrials.gov , the EU Clinical Trials Information System (CTIS) , or the ISRCTN registry